Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration

Author： Dittrich C.   Greim G.   Borner M.   Weigang-Kohler K.   Huisman H.   Amelsberg A.   Ehret A.   Wanders J.   Hanauske A.   Fumoleau P.   for the EORTC Early Clinical Studies Group ECSG  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.38, Iss.8, 2002-05, pp. : 1072-1080

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse

By Baumann M.   Krause M.   Zips D.   Eicheler W.   Dörfler A.   Ahrens J.   Petersen C.   Brüchner K.   Hilberg F.  

International Journal of Radiation Biology, Vol. 79, Iss. 7, 2003-07 ,pp. : 547-559

Informa Healthcare

Access to resources Recommend Favorite

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101

By Adamson P.   Blaney S.   Widemann B.   Kitchen B.   Murphy R.   Hannah A.   Cropp G.   Patel M.   Gillespie A.   Whitcomb P.   Balis F.M.  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 6, 2004-06 ,pp. : 482-488

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer

By Arnoletti J.   Frolov A.   Eloubeidi M.   Keene K.   Posey J.   Wood T.   Greeno Edward   Jhala N.   Varadarajulu S.   Russo S.   Christein J.   Oster R.   Buchsbaum D.   Vickers S.  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 891-897

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

By Awada A.   Eskens F.A.L.M.   Piccart M.   Cutler D.L.   van der Gaast A.   Bleiberg H.   Wanders J.   Faber M.N.   Statkevich P.   Fumoleau P.   Verweij J.   for the EORTC Early Clinical Studies Group  

European Journal of Cancer, Vol. 38, Iss. 17, 2002-11 ,pp. : 2272-2278

Elsevier

Access to resources Recommend Favorite

EGFRIndb: Epidermal Growth Factor Receptor Inhibitor Database

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 7, 2014-09 ,pp. : 928-935

Bentham Science Publishers

Access to resources Recommend Favorite